3种方案根除幽门螺杆菌的药物经济学分析

目的观察3种方案根除幽门螺杆菌（helicobacter pylori,Hp）药物成本与效果的关系。方法 182例患者随机分为3组：A组64例,给予雷贝拉唑10mg,克拉霉素0.5g,呋喃唑酮0.1g,每天2次;B组61例,给予奥美拉唑20mg,呋喃唑酮0.1g,替硝唑0.4g,每天2次;C组57例,给予奥美拉唑20mg,克拉霉素0.5g,阿莫西林1.0g,每天2次;1周后停药并分析疗效及药物经济学。结果 3种方案药品成本分别为148.40、8.55、146.95元,有效率分别为92.2%、90.2%、86.0%,差异无统计学意义（P〉0.05）;B组成本-效果分析及敏感度均优于A组和C组,差异均有统计学意义（P〈0.05）。结论 A治疗方案疗效可靠,价格合理,经济条件较好可以使用;B方案疗效可靠,价格便宜,农村患者可以推广;C方案疗效稍逊一筹,价格昂贵,不宜推广。

Cost-benefit analysis of three schedule for treating helicobacter pylori

Objective To observe the relations between drug cost and effectiveness of3 kinds for helicobacteria pylori （Hp）. Methods 182 patietns were randomly assigned to receive colloidal rabeprazole 10mg ＋ clarithromycin 0. 5g ＋ furazoli-done 0. 1g（group A,64 cases）,2 times a day;Colloidal omeprazole 20mg ＋ furazolidone 0. 1g ＋ Tinidazole 0. 4g（group B,61 cases）,2 times a day;Colloidal omeprazole 20mg ＋ clarithromycin 0. 5g ＋ amoxicillin 1. 0g（group C,57 cases）,2 times a day. The course of treatment was l week for three groups,and analysed the efficacy and pharmacoeconomics. Results The cost of 3 kinds of pharmacotherapentic schemes were 148. 40,8. 55 and 146. 95 yuan,the eradication rates of helicobacter pylori were 92. 2% ,90. 2% and 86. 0% ,the difference was not statistically significant（P 0. 05）;Cost-effectiveness analysis and sensitivity of B group were better than that in A group and C group,the differences were statistically significant（P 0. 05）. Conclusion The pharmacotherapentic schemes of A was effective,not so expensive,can be used for the patients who were rich;The pharmaeotherapentic schemes of B was cheap while effective in helieobacter pylofi eradication,can be used clinically;The phar-macotherapentic schemes of C was so expensive while poor effective,can not be used clinically.